Treatment progress of relapsed/refractory peripheral T-cell lymphoma
10.3760/cma.j.cn115356-20221230-00365
- VernacularTitle:复发难治外周T细胞淋巴瘤治疗进展
- Author:
Jili DENG
1
;
Chen ZHANG
;
Yuqin SONG
Author Information
1. 北京大学肿瘤医院暨北京市肿瘤防治研究所淋巴肿瘤内科 恶性肿瘤发病机制及转化研究教育部重点实验室，北京 100142
- Keywords:
Lymphoma, peripheral T-cell;
Recurrence;
Relapse;
Treatment
- From:
Journal of Leukemia & Lymphoma
2023;32(1):18-21
- CountryChina
- Language:Chinese
-
Abstract:
Peripheral T-cell lymphoma (PTCL) is a highly heterogeneous disease with numerous subtypes, and the overall prognosis is poor, especially in relapsed/refractory patients, and the patients are generally older with limited treatment options that can be tolerated. At the 64th American Society of Hematology (ASH) Annual Meeting in 2022, studies on relapsed/refractory PTCL include the combination of epigenetic agents or combination of immune checkpoint inhibitors, CD30 antibody-drug conjugate (ADC) brentuximab vedotin combined with chemotherapy, targeted drugs PI3K inhibitors and JAK1 inhibitors, etc., providing more choices and opportunities for relapsed/refractory patients.
